Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03948334 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 123
- Enrollment target
NCT03948334 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 123 participants.
The verdict
NCT03948334, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 123 participants
- Enrollment target
Study Summary
This extension study (CZPL389A2203E1) was designed as a 2-year (100 weeks) extension to the core study (CZPL389A2203/ NCT03517566) which is disclosed separately. It aimed to assess the short-term and long-term safety of (blinded) 30 mg o.d and 50 mg o.d ZPL389 with concomitant or intermittent use of topical corticosteroids (TCS) and/or topical calcineurin inhibitors (TCI).
Interventions
- DRUG ZPL389 30mg
- DRUG ZPL389 50mg
- DRUG TCS and/or TCI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2019-04-04 |
| Est. Completion | 2020-08-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03948334
The ClinicalTrials.gov registry entry for NCT03948334 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which ZPL389 30mg is the first listed.
NCT03948334 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03948334 about?
NCT03948334 is a clinical study titled "A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients". This extension study (CZPL389A2203E1) was designed as a 2-year (100 weeks) extension to the core study (CZPL389A2203/ NCT03517566) which is disclosed separately. It aimed to assess the short-term and long-term safety of (blinded) 30 mg o.d and 50 mg o.d ZPL389 with concomitant or intermittent use of...
What is the current status of trial NCT03948334?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 123 participants. The study started on 2019-04-04. Estimated completion is 2020-08-25.
What interventions are being tested in trial NCT03948334?
The interventions under investigation include: ZPL389 30mg (DRUG), ZPL389 50mg (DRUG), TCS and/or TCI (DRUG).
Who is sponsoring clinical trial NCT03948334?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.